Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Trump Drug Ad Crackdown: FDA Warns Novo Nordisk, Eli Lilly, Hims
04:45pm, Tuesday, 16'th Sep 2025
The Food and Drug Administration sent warning letters to dozens of drug companies— including popular telehealth firm Hims & Hers and pharmaceutical giants Eli Lilly and Novo Nordisk— demanding the
Stock Of The Day: Is The Novo Nordisk Death Spiral Finally Over?
12:25pm, Tuesday, 16'th Sep 2025
Novo Nordisk A/S NVO is trading higher on Friday. It is just below resistance around the $58 level.
LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
"Reassessment" of LLY & NVO GLP-1 Projections Set New Guidance Tone
11:30am, Tuesday, 16'th Sep 2025
Lee Brown offers investor insight in the GLP-1 space in what he calls an industry with "expanding opportunity." He believes consumer sentiment has reset to proper expectations following sell-offs in E
Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment
10:50am, Tuesday, 16'th Sep 2025
U.S.-listed shares of Novo Nordisk (NVO) gained after the drugmaker reported positive results from a late-stage study of a weight-loss drug that works differently than traditional GLP-1 inhibitors.
Is Novo Nordisk TV Ad Buying Fueling Stock Price?
10:49am, Tuesday, 16'th Sep 2025
While Novo Nordisk (NYSE: NVO) did not win an Emmy, the company has spent $96 million in Q2 alone on TV ads. And I am sure if one queried a random group of actors, we might discover that taking one di
Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment
10:21am, Tuesday, 16'th Sep 2025
Novo Nordisk A/S NVO reportedly said on Tuesday that it intends to seek US regulatory approval for a high-dose version of its weight-loss injection Wegovy (semaglutide), another effort to counter Eli
Novo Nordisk shares higher on positive Phase 3 trial results for obesity drug Cagrilintide
09:59am, Tuesday, 16'th Sep 2025
Novo Nordisk (NYSE:NVO) shares gained on Tuesday after the company reported promising Phase 3 trial results for its experimental weight-loss drug Cagrilintide, presented at the European Association fo
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
09:56am, Tuesday, 16'th Sep 2025
Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline
08:45am, Tuesday, 16'th Sep 2025
NEW YORK , Sept. 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Novo Nordisk to test weight-loss drugs in broader range of obesity-linked conditions
07:54am, Tuesday, 16'th Sep 2025
Novo Nordisk plans to examine in clinical trials whether its future weight-loss drugs can treat a wide range of health conditions linked to obesity, as it has already begun doing with its blockbuster
Novo Nordisk flags drug trial promise amid hunt for next weight-loss blockbuster
07:26am, Tuesday, 16'th Sep 2025
Cagrilintide is a long-acting amylin analogue, a nascent form of weight loss treatment which differs existing GLP-1s. Phase 3 trial results showed the once-weekly Cagrilintide monotherapy injection he
Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme
06:00am, Tuesday, 16'th Sep 2025
Bagsværd, Denmark, 16 September 2025 – Novo Nordisk today presented data from a sub-analysis of the phase 3 REDEFINE 1 trial at the European Association for the Study of Diabetes (EASD) congress 20
Novo Nordisk's Wegovy Helps Suppress Thoughts About Food, Study Suggests
02:57am, Tuesday, 16'th Sep 2025
The number of people who reported experiencing constant thoughts about food declined by 46% after starting treatment with Wegovy, the pharma giant said.
The Secret Blue-Chip Rally No One Knows About: 4 Amazing Ideas To Consider
07:01pm, Monday, 15'th Sep 2025
People might be shocked to learn the Mag 7 are not in a bubble. The PEGY ratio of 0.9 to 1.0 confirms Morningstar's fair value estimate. However, you might be even more shocked to discover that value
